A detailed history of Advisor Group Holdings, Inc. transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,377 shares of IMCR stock, worth $43,857. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,377
Previous 1,071 28.57%
Holding current value
$43,857
Previous $36,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$30.06 - $41.49 $9,198 - $12,695
306 Added 28.57%
1,377 $42,000
Q2 2024

Aug 13, 2024

SELL
$33.78 - $63.75 $3,850 - $7,267
-114 Reduced 9.62%
1,071 $36,000
Q1 2024

May 10, 2024

SELL
$60.14 - $75.36 $89,909 - $112,663
-1,495 Reduced 55.78%
1,185 $77,000
Q4 2023

Feb 12, 2024

SELL
$42.85 - $69.5 $3,556 - $5,768
-83 Reduced 3.0%
2,680 $183,000
Q3 2023

Nov 13, 2023

BUY
$49.5 - $66.6 $40,441 - $54,412
817 Added 41.98%
2,763 $143,000
Q2 2023

Aug 10, 2023

BUY
$48.54 - $61.64 $58,102 - $73,783
1,197 Added 159.81%
1,946 $116,000
Q1 2023

May 12, 2023

BUY
$46.12 - $65.71 $922 - $1,314
20 Added 2.74%
749 $37,000
Q4 2022

Feb 10, 2023

BUY
$45.51 - $65.08 $500 - $715
11 Added 1.53%
729 $41,000
Q3 2022

Nov 14, 2022

BUY
$37.34 - $57.44 $5,003 - $7,696
134 Added 22.95%
718 $33,000
Q1 2022

May 04, 2022

BUY
$18.94 - $34.29 $8,731 - $15,807
461 Added 374.8%
584 $17,000
Q3 2021

Nov 05, 2021

SELL
$27.98 - $40.0 $167 - $240
-6 Reduced 4.65%
123 $4,000
Q2 2021

Aug 02, 2021

BUY
$32.22 - $41.5 $225 - $290
7 Added 5.74%
129 $5,000
Q1 2021

May 13, 2021

BUY
$36.3 - $56.34 $4,428 - $6,873
122 New
122 $5,000

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.4B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.